se of probiotics in asymptomatic vaginal infectio
Not Applicable
Recruiting
- Conditions
- Bacterial vaginosis
- Registration Number
- RBR-36fh5ss
- Lead Sponsor
- eila Cristina Soares Brollo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
18 to 50 years, in pre-menopause, with cytology result indicating supracytoplasmic bacilli microbiota, no complaints
Exclusion Criteria
pregnant women, postmenopausal women, with immunosuppressive diseases or using immunosuppressive medication
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie probiotic efficacy in asymptomatic bacterial vaginosis (RBR-36fh5ss)?
How do probiotics compare to metronidazole in managing asymptomatic bacterial vaginosis recurrence rates?
Which vaginal microbiome biomarkers predict response to probiotic therapy in RBR-36fh5ss trial participants?
What adverse events are associated with long-term probiotic use for bacterial vaginosis prevention?
Are there synergistic effects when combining Lactobacillus strains with prebiotics for bacterial vaginosis treatment?